Biotechnology company Alligator Bioscience (STO:ATORX) said on Thursday that it has decided to focus its resources on two proprietary candidate drugs, ATOR-1017 and mitazalimab.
Positive safety and strong Proof of Mechanism data support moving both of these potential new cancer treatments into clinical efficacy (Phase Ib/II) studies in 2021, the company said.
According to Alligator Bioscience CEO Per Norlén, ATOR-1017 and mitazalimab both have potential in "large cancer indications with high medical need and billion-dollar markets".
Alligator will complete the ongoing dose-escalation study with the bispecific ATOR-1015 as planned during the fourth quarter of 2020, after which it will be partnered for further development.
Innovent expands global Phase 3 study of IBI363/TAK-928 to include non-squamous NSCLC
Lundbeck to relocate US headquarters to Greater Boston
FDA approves WELIREG and LENVIMA combination for previously treated advanced renal cell carcinoma
AstraZeneca's IMFINZI combination receives US Priority Review for muscle-invasive bladder cancer
Novotech to acquire Agilex Biolabs from Healius
ACROBiosystems launches CHO-Direct and ACRO AIx to accelerate AI-driven drug discovery
UChicago Medicine completes construction phase of new cancer facility
Viking Therapeutics plans offerings of common stock and convertible senior notes
Astellas doses first patient in Phase 3 lung cancer study
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
Ondine Biomedical deployssteriwave across five Southern Ontario hospitals
Ionis reports positive Phase 3 sefaxersen data in IgA nephropathy
X-Chem and Relay Therapeutics collaborate on Phase 3 milestone